Cargando…
Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma
A Japanese subgroup analysis from the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) was performed to evaluate the efficacy and safety outcomes of the Japanese population. In this Asian phase II study, darinaparsin was administered to 6...
Autores principales: | Negoro, Eiju, Yamauchi, Takahiro, Fukuhara, Noriko, Yamamoto, Kazuhito, Uchida, Toshiki, Izutsu, Koji, Maruyama, Dai, Terui, Yasuhito, Nakajima, Hideaki, Ando, Kiyoshi, Suehiro, Youko, Choi, Ilseung, Kanemura, Nobuhiro, Nakamura, Nobuhiko, Yamamoto, Go, Maeda, Yoshinobu, Shibayama, Hirohiko, Nagahama, Fumiko, Sonehara, Yusuke, Nagai, Hirokazu, Tien, Hwei-Fang, Kwong, Yok-Lam, Kim, Won-Seog, Tobinai, Kensei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JSLRT
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410617/ https://www.ncbi.nlm.nih.gov/pubmed/37380467 http://dx.doi.org/10.3960/jslrt.23005 |
Ejemplares similares
-
Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
por: Kim, Won-Seog, et al.
Publicado: (2023) -
Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea
por: Ogura, Michinori, et al.
Publicado: (2020) -
Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2020) -
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma
por: Terui, Yasuhito, et al.
Publicado: (2021) -
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
por: Izutsu, Koji, et al.
Publicado: (2023)